Reductil, also known as sibutramine, is a medication used to treat obesity by giving the patient a feeling of fullness to limit food intake. It is potentially addictive and has been linked to cardiac events. It is no longer prescribed in the UK and is surpassed in the market by Orlistat.
Reductil is a medication used in the treatment of obesity. It is commonly known as sibutramine and is sold under various names, including Sibutrex, Meridia, and Reductil. The drug works by giving the patient a feeling of fullness, which is aimed at limiting food intake. It is known to be potentially addictive and as such is on a restricted drug list in the US.
This drug is a stimulant and shares some similarities in chemical structure with amphetamines, although its function in the brain is different. Reductil works by blocking the reuptake, also known as reuptake, of the neurotransmitter serotonin. The result is an increased amount of serotonin in the brain, which has been linked to reduced appetite. Reductil usually comes in doses of five, ten, and 15 milligrams, and is administered orally.
Medications like Reductil are only recommended for those who have tried other weight loss programs without success, and are medically identified as obese. A body mass index (BMI) of more than 30 kg/m2 is usually required for these recipes. An individual with a slightly lower BMI and other risk factors, such as high blood pressure or diabetes, may also be prescribed this medication. Weight loss while using it will come gradually.
Sibutramine-based medications were approved by the US Food and Drug Administration (FDA) in 1997. Side effects can include dizziness, drowsiness, upset stomach, and increased appetite despite feeling full. There are also concerns about the effects it has on heart function. In November 2009, the FDA issued a statement regarding a study that showed a potential connection between this drug and cardiac events, such as heart attack or stroke. Sibutramine-based medicines should not be prescribed to people with low-functioning kidneys or pre-existing heart problems.
As of January 2010, doctors in the UK no longer prescribe Reductil and other drugs containing Sibutramine. This was in response to a recommendation from the European Medicines Agency (EMA), which called for the drug’s license to be revoked in Europe. A patient who wishes to discontinue the use of Reductil can do so immediately without adverse side effects.
Although common, Reductil is surpassed in the world market by Orlistat. This medication is marketed as Alli or Xenical. Instead of blocking the reuptake of serotonin, these drugs prevent fat from food from being broken down and used by the body.
Protect your devices with Threat Protection by NordVPN
